交易 Fulcrum Therapeutics Inc - FULC
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule that is in Phase 2b clinical trial for the treatment of facioscapulohumeral muscular dystrophy, a rare, progressive, and disabling muscle wasting disorder that leads to significant physical impairments and disability; and FTX-6058, a small molecule designed to upregulate fetal hemoglobin in patients with sickle cell disease and ß-thalassemia. The company is also discovering drug targets for the treatments of muscle, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has research and discovery collaboration agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and has a strategic collaboration and license agreement with MyoKardia, Inc. to discover, develop, and commercialize novel targeted therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.最新股票文章
台積電股價預測：第三方目標價
台灣積體電路製造公司（TSM）在2025年9月25日UTC下午4時55分報276.65美元，盤中區間介於270.91美元至282.95美元之間。
08:56, 3 11月 2026
IonQ 股價預測：第三方目標價
IonQ 開發囚禁離子量子系統，2026 年第一季調整後 EBITDA 虧損 9,680 萬美元，同時致力打造 256 量子位元系統。探索第三方 IONQ 目標價與技術分析。過往表現並非未來結果的可靠指標。
09:45, 30 10月 2026
Uber Technologies 股價預測：裁減 3,300 個職位，拓展機械人計程車業務
Uber 正進行重組，裁減約 3,300 個職位，同時在機械人計程車市場競爭加劇之際，擴大自動駕駛汽車合作關係。本文整理第三方對 UBER 的股價目標及技術分析。過往表現並非未來業績的可靠指標。
10:51, 2 10月 2026
評級和評論
評級和評論
